Market access for medicines in times of austerity
226 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by PatientView
Scoop.it!

Better information would improve cancer management, according to PatientView survey

Better information would improve cancer management, according to PatientView survey | Market access for medicines in times of austerity | Scoop.it
PatientView's insight:

Survey done w/ support from @AstraZeneca shows #cancer patients want easier to understand, actionable info on disease and treatment

more...
rob halkes's curator insight, October 7, 8:58 AM

The more cooperation between patient groups and health industry, the more the really relevant and significant information can be researched to better health outcomes!

rob halkes's curator insight, October 7, 9:06 AM

Grt example of how big pharma supports healthcare provision, by generating significant patient needs!

Scooped by PatientView
Scoop.it!

NHS can fund 'game-changing' PrEP HIV drug, court says

NHS can fund 'game-changing' PrEP HIV drug, court says | Market access for medicines in times of austerity | Scoop.it
NHS England to appeal against judgment ruling it has legal power to fund drugs that are highly effective in preventing HIV
PatientView's insight:

Some negative media coverage on the decision focusing on that out-dated notion of "sin diseases"

more...
No comment yet.
Scooped by PatientView
Scoop.it!

High cost of new drugs

Why government must negotiate a better deal for publicly funded research

The investigation by The BMJ and Cambridge and Bath universities into the availability of breakthrough hepatitis C drugs raises important questions for NHS England about access to lifesaving drugs.1 However, the main question is why medicines are so expensive in the first place. The pricing strategy of Gilead for sofosbuvir (Sovaldi) and ledipasvir-sofosbuvir (Harvoni) raises questions that go well beyond the UK.

The BMJ ’s investigation is just an example of a more general problem. What is the right price to pay for a particular drug, and how should this be determined?

Pharmaceutical innovation should be structured so that it focuses on unmet health needs globally and delivers therapeutic advances that are affordable and accessible to all,2 not just profitable for manufacturers. This requires an approach that directs effort towards therapeutic innovations rather than “me too” drugs, and a financing and pricing structure which is transparent, focused on access, and reflects the collective investment and risk taking involved.

Drug companies have often …
PatientView's insight:

BMJ editorial on drug pricing and a call for transparency

more...
No comment yet.
Scooped by PatientView
Scoop.it!

ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe

ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe | Market access for medicines in times of austerity | Scoop.it
PatientView's insight:

ESMO study defines the disparities in access to cancer medicines

more...
No comment yet.
Rescooped by PatientView from CORPORATE REPUTATION-THE PATIENT PERSPECTIVE
Scoop.it!

US pharmaceutical company defends 5,000% price increase - BBC News

The head of a US pharmaceutical company defends a decision to raise the price of a 62-year-old medication used by Aids patients by over 5,000%.
more...
PatientView's curator insight, September 24, 2015 12:35 PM

Is turning a profit the only criteria when pricing a drug?

Rainmaker Healthcare Communications's curator insight, September 28, 2015 3:33 AM

Is profit the key criteria when pricing a drug?

Rescooped by PatientView from The patient movement
Scoop.it!

Health Care Coverage and Access for Men, 2013-2015

Health Care Coverage and Access for Men, 2013-2015 | Market access for medicines in times of austerity | Scoop.it
This Visualizing Health Policy infographic provides a snapshot of men’s health care and insurance coverage issues, including health status, access to care, and use of services. It compares the uninsured rates of men and women; their cost barriers to care; their connection to clinicians; and...
more...
PatientView's curator insight, July 18, 2015 6:41 AM

Men and access to helathcare in the USA infographic

Scooped by PatientView
Scoop.it!

Impatient patients demand drug fix

Impatient patients demand drug fix | Market access for medicines in times of austerity | Scoop.it
Two major groups surprised industry with their specific demands for “a European approach to the market.”
PatientView's insight:

Patients take the initiative on drug pricing 

more...
No comment yet.
Scooped by PatientView
Scoop.it!

Pharmaceutical Industry Doing More to Improve Access to Medicine in Developing Countries; Performance on Some Aspects Lags

Pharmaceutical Industry Doing More to Improve Access to Medicine in Developing Countries; Performance on Some Aspects Lags | Market access for medicines in times of austerity | Scoop.it
AMSTERDAM, November 17, 2014 /PRNewswire/ --

The world's leading pharmaceutical companies are doing more to improve...
PatientView's insight:

Interesting that @PatientView does not get the same rankings for corporate reputation 

more...
No comment yet.
Rescooped by PatientView from The patient movement
Scoop.it!

Access Our Medicine Initiative | Affordable Medicine

Access Our Medicine Initiative | Affordable Medicine | Market access for medicines in times of austerity | Scoop.it
Everyone should have access to affordable medicine - declare it. Sign the declaration.
more...
PatientView's curator insight, November 8, 2014 5:57 AM

Just came across this site via MS International 

Rescooped by PatientView from The patient movement
Scoop.it!

New report: Patient groups and their impact on access to medicines

New report: Patient groups and their impact on access to medicines | Market access for medicines in times of austerity | Scoop.it
more...
No comment yet.
Scooped by PatientView
Scoop.it!

2014 01 Boris Azais - How Pharmaceutical companies are transformi...

Pharmaceutical innovation, research and development, and business model
PatientView's insight:

Patients are mentioned on slide 29

more...
No comment yet.
Scooped by PatientView
Scoop.it!

Is the increasing cost of treating rare diseases sustainable?, Expert Opinion on Orphan Drugs, Informa Healthcare

Is the increasing cost of treating rare diseases sustainable?, Expert Opinion on Orphan Drugs, Informa Healthcare | Market access for medicines in times of austerity | Scoop.it
PatientView's insight:

With the advent of personalized medicines the majority of diseases are set to become rare diseases 

more...
No comment yet.
Scooped by PatientView
Scoop.it!

Campaign cuts through red tape to get men with prostate cancer in Wales access to benefits of earlier chemotherapy

Campaign cuts through red tape to get men with prostate cancer in Wales access to benefits of earlier chemotherapy | Market access for medicines in times of austerity | Scoop.it
Eligible men in Wales with newly diagnosed advanced prostate cancer will now be offered earlier access to docetaxel chemotherapy alongside hormone therapy. Combining these treatments has been shown to offer these men the possibility of an extra fifteen months of life on average.
PatientView's insight:

Patient campaignimg gets men in Wales access to early chemo

more...
No comment yet.
Scooped by PatientView
Scoop.it!

Betting on hepatitis C: how financial speculation in drug development influences access to medicines

Victor Roy and Lawrence King argue that the acquisition strategies of drug companies magnify development costs and leave the public paying twice—for research and high priced medicines

Sofosbuvir based medicines have marked an important breakthrough for patients with hepatitis C infection, offering cure rates of over 90%. The virus is a leading infectious killer globally, disproportionately affecting vulnerable groups such as people who inject drugs or have HIV/AIDS.1 Even after discounts offered from a US list price of about $90 000 (£70 000; €80 000) per three month treatment course, however, the cost of these drugs, manufactured by Gilead Sciences, has challenged government budgets and led to rationing. Sofosbuvir’s pricing has been at the centre of a global debate over the affordability of prevailing systems of drug development, and the US Senate conducted an 18 month investigation into Gilead’s pricing strategy and its consequences for health budgets and patient access.2

One argument for the high prices has been that the curative drugs represent a major advance in value to patients and health systems. They are indeed more cost effective than many expensive medicines that provide only marginal benefit. Yet the company’s ability to charge high prices ultimately relies on monopoly protections via patents, which the industry has long argued are necessary to encourage costly research and development. Critics, however, charge that these costs are exaggerated.3 4 5

We use the case of hepatitis C to highlight another dynamic missing from the debate: the financial model driving large companies and their shareholders. To maximise growth in earnings, large companies like Gilead often enter expensive bidding contests to acquire companies with promising compounds. Subsequent profits are then directed back to shareholders rather than invested in early stage research. This speculative cycle propels the prices of medicines and impedes affordable access for both …
PatientView's insight:

The editorial from the BMJ on drug pricing and R&D

more...
No comment yet.
Scooped by PatientView
Scoop.it!

Government listing of clinical trials doesn't offer patient costs

Government listing of clinical trials doesn't offer patient costs | Market access for medicines in times of austerity | Scoop.it
The ClinicialTrials.gov website, run by the National Institutes of Health, doesn't require trial sponsors to disclose charges to patients.
PatientView's insight:

US patient groups want clinical trials.gov also to publish prices of treatment and care

more...
No comment yet.
Scooped by PatientView
Scoop.it!

Filling A Prescription? You Might Be Better Off Paying Cash

Filling A Prescription? You Might Be Better Off Paying Cash | Market access for medicines in times of austerity | Scoop.it
Amid growing concern about rising drug costs, the practices of prescription benefit management firms are drawing a new level of attention.
PatientView's insight:

Prescription prices up 30% in USA- KH survey says

more...
No comment yet.
Scooped by PatientView
Scoop.it!

What the ‘Shocking’ Gilead Discounts on its Hepatitis C Drugs Will Mean - Pharmalot - WSJ

What the ‘Shocking’ Gilead Discounts on its Hepatitis C Drugs Will Mean - Pharmalot - WSJ | Market access for medicines in times of austerity | Scoop.it
The news that Gilead Sciences will offer bigger discounts on its hepatitis C drugs this year prompted Wall Street to set a cap on the overall market for these drugs.
PatientView's insight:

Often drug discounts are opaque which undermines a propeer functioning market

more...
No comment yet.
Scooped by PatientView
Scoop.it!

New drug may attack Alzheimer's underlying cause, study finds

New drug may attack Alzheimer's underlying cause, study finds | Market access for medicines in times of austerity | Scoop.it
More than five million Americans live with Alzheimer's disease. Research coming out from the Alzheimer's Association Conference in Washington looks at an experimental drug, solanezumab. The treatment may attack the underlying cause and slow the devastating illness' progress. Dr. David Agus joins "CBS This Morning" to discuss the effects of the drug.
PatientView's insight:

Let's hope governments can afford the new dementia drug

more...
No comment yet.
Scooped by PatientView
Scoop.it!

Disappointment for pharma with new Cancer Drugs Fund list - PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list - PMLiVE | Market access for medicines in times of austerity | Scoop.it
PatientView's insight:

This is why we need a new mechanism for drug pricing in Europe

more...
No comment yet.
Scooped by PatientView
Scoop.it!

In Big Shift, 23andMe Will Invent Drugs Using Customer Data

In Big Shift, 23andMe Will Invent Drugs Using Customer Data | Market access for medicines in times of austerity | Scoop.it
23andMe CEO and Founder Anne Wojcicki 23andMe, the Google-backed personal genetics startup, will no longer just sell tests to consumers, or genetic data to pharmaceutical companies. This morning, it announced that it plans to start inventing medicines itself. It’s not just talk. The company has hired Richard Scheller, who led drug discovery [...]
more...
No comment yet.
Scooped by PatientView
Scoop.it!

Green Mediabox | recorded events

PatientView's insight:

Can we afford our medicines? Conference at the European Parliament 

more...
No comment yet.
Rescooped by PatientView from Market access for medicines in times of austerity
Scoop.it!

New report: Patient groups and their impact on access to medicines

New report: Patient groups and their impact on access to medicines | Market access for medicines in times of austerity | Scoop.it

Via PatientView
more...
No comment yet.
Scooped by PatientView
Scoop.it!

Contestable fund for medicines for rare disorders | PHARMAC

Contestable fund for medicines for rare disorders | PHARMAC | Market access for medicines in times of austerity | Scoop.it
PatientView's insight:

How New Zeland is trying to cope with access to medicines for rare disorders

more...
No comment yet.
Scooped by PatientView
Scoop.it!

Millennium Development Goals - Health Poverty Action

Millennium Development Goals - Health Poverty Action | Market access for medicines in times of austerity | Scoop.it
In 2000, eight Millennium Development Goals were agreed by the United Nations to tackle poverty, health, education, equality and the environment.
PatientView's insight:

As the gap between the health status of the rich and poor ever widens the onus on pharma increases to help bridge the gap

more...
No comment yet.